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Loop, Houston, TX 77030, Abstract—Background: Emergency physicians make
treatment decisions in patients who present to the emergency
department (ED) with acute venous thromboembolism
(VTE). They also encounter patients on target-specific oral
anticoagulants (TSOACs) who require urgent intervention.
New approvals and increasing prescriptions for TSOACs
(e.g., apixaban, dabigatran, edoxaban, and rivaroxaban)
for the management of several thromboembolic disorders
warrant an evaluation of the impact of these agents in the
ED setting. Objective of the Review: This review discusses
the use of TSOACs in the ED for the treatment of acute
VTE, and highlights strategies for the management of
patients on TSOACs who present to the ED with other com-
plications, such as bleeding complications or requiring emer-
gency surgery. Discussion: Apixaban, dabigatran, edoxaban,
and rivaroxaban have been approved for the treatment of
acute VTE.We discuss the impact of this on EDmanagement
of TSOAC-naı¨ve patients and highlight results with TSOACs
in high-risk subgroups including the elderly and those with
prior VTE or active cancer. This review also discusses
management strategies for patients on TSOACs. For emer-
gency physicians, strategies for the management of bleeding,
approaches to patient care when emergency surgery is
needed, laboratory assays for measuring plasma concentra-
tions of TSOACs, and drug–drug interactions are of special
importance. Conclusions: Familiarity with TSOACs will
better position emergency physicians to provide state-of-
the art care to their patients with VTE and help them
manage potentially complicated circumstances related
to the chronic use of these drugs.  2016 The Authors.
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Target-specific oral anticoagulants (TSOACs), including
the direct Factor Xa inhibitors apixaban and rivaroxaban,
and the direct thrombin inhibitor dabigatran etexilate, are
increasingly prescribed for patients who are at risk of, or
who have been diagnosed with, thromboembolic disor-
ders. Apixaban and rivaroxaban have been approved as
single-drug approaches in many countries, including the
United States, for the treatment of acute deep vein throm-
bosis (DVT) or pulmonary embolism (PE), and for
the prevention of recurrent DVT or PE (Table 1) (1,2).
Dabigatran and edoxaban have been approved in the
United States (dabigatran also in the European Union)
for the treatment of DVT and PE in patients who
have been treated with a parenteral anticoagulant for
5–10 days (3,4). Dabigatran also has been approved for
the prevention of recurrent venous thromboembolism
(VTE) (3). Apixaban, dabigatran, edoxaban, and rivarox-
aban have all been approved for the prevention of stroke
and systemic embolism in patients with nonvalvular atrial
fibrillation (Table 1) (1–4). In addition, rivaroxaban hasary 2015;
Table 1. Dosing Regimens of Apixaban, Dabigatran Etexilate, Edoxaban, and Rivaroxaban in Adult Patients for Approved
Indications in the United States. (1–4)
Approved Indications Apixaban Dabigatran Etexilate Edoxaban Rivaroxaban
Prevention of stroke
and systemic
embolism in patients
with nonvalvular AF
5 mg b.i.d. (2.5 mg b.i.d.
in patients with two
of the following
characteristics:
 Age $80 years
 Bodyweight #60 kg
 Serum creatinine
$1.5 mg/dL)
150 mg b.i.d.
(75 mg b.i.d. in
patients with CrCl
15–30 mL/min)
60 mg o.d. in patients
with CrCl
>50–#95 mL/min
20 mg o.d. (15 mg o.d.
in patients with CrCl
15–50 mL/min)
VTE prevention after
elective hip or knee
replacement surgery
2.5 mg b.i.d. Not approved 30 mg o.d. in patients
with CrCl 15–50
mL/min
10 mg o.d.
Treatment of DVT or PE 10 mg b.i.d. for 7 days;
5 mg b.i.d. thereafter
After 5–10 days
parenteral therapy:
150 mg b.i.d.
Not approved in
patients with
CrCl >95 mL/min
15 mg b.i.d. for
3 weeks; 20 mg o.d.
thereafter
Prevention of recurrent
DVT and PE
2.5 mg b.i.d. 150 mg b.i.d. Not approved 20 mg o.d.
AF = atrial fibrillation; b.i.d. = twice daily; CrCl = creatinine clearance; DVT = deep vein thrombosis; o.d. = once daily; PE = pulmonary
embolism; VTE = venous thromboembolism.
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hip or knee replacement surgery (Table 1) (1); dabigatran
also has been approved for this indication in the European
Union, and edoxaban has been approved in Japan for the
prevention of VTE after major orthopedic surgery (3).
Apixaban has been approved in the United States for
the prevention of DVT that may lead to a PE in patients
who have undergone hip or knee replacement surgery.
In the European Union (but not the United States), low-
dose rivaroxaban in combination with antiplatelet therapy
also has been approved for secondary prevention after
acute coronary syndrome in patients with elevated
biomarkers.
There is a need to evaluate the impact of these agents
in the emergency department (ED) setting. Emergency
physicians are often responsible for the initial diagnosis
of acute DVT and PE, and subsequent treatment deci-
sions. Furthermore, they will encounter patients who
are taking TSOACs and present to the ED with active
bleeding or conditions that may require urgent invasive
intervention. Therefore, emergency physicians must be
not only familiar with the TSOACs and their approved
indications, but also be prepared to manage patients in
emergency situations who are taking these anticoagulants
when they present to the ED.
TSOACs address many of the practical management
challenges of traditional agents, including unfractio-
nated heparin (UFH), low-molecular-weight heparin
(LMWH), fondaparinux, and vitamin K antagonists
(VKAs). TSOACs have the benefit of convenient oral
administration, a fixed-dose regimen, fast onset of
action (which is similar to the onset of action of enoxa-parin), minimal drug–drug interactions, no dietary
restrictions, no risk of patients developing heparin-
induced thrombocytopenia, and no requirement for
routine coagulation monitoring (5,6). Owing to these
characteristics, TSOACs are becoming increasingly
important in ED clinical practice.
The objectives of this article are to discuss the poten-
tial impact of the use of TSOACs in the ED for the
treatment of acute DVT and PE, and to highlight the
need for clear strategies for the management of patients
on TSOACs who present to the ED with other complica-
tions.
DISCUSSION
Guidelines for the Treatment of Venous
Thromboembolism
The American College of Chest Physicians (ACCP)
recommends initial treatment with either parenteral anti-
coagulation by LMWH, fondaparinux, or intravenous
UFH, or oral anticoagulation with rivaroxaban (7). These
guidelines also mention dabigatran as an alternative
option for the treatment of VTE, despite dabigatran not
being widely approved at the time (7). Apixaban and edox-
aban were only recently approved and are expected to be
recommended as treatment options in future guidelines
for the treatment of VTE. In patients who receive tradi-
tional standard-of-care therapy (comprising initial paren-
teral therapy overlapping with and followed by VKA),
parenteral bridging therapy is recommended for a mini-
mum of 5 days and until the international normalized ratio
(INR) is 2.0 or above for at least 24 h. In clinical studies,
Table 3. Risk Score for Major Bleeding During the First
248 W. F. Peacock et al.dabigatran and edoxaban were also given after initial
parenteral bridging therapy, whereas rivaroxaban and apix-
aban were given as single-drug therapies. Anticoagulation
therapy for the treatment of acute DVTor PE is recommen-
ded for at least 3 months (7). Extended treatment is recom-
mended in patients with active cancer or in patients with a
first unprovoked VTE who have a low-to-moderate risk of
bleeding (7). The optimal treatment duration in patients
with acute DVT or PE remains a matter of debate.
In patients with acute proximal DVT of the leg, anti-
coagulant therapy alone is recommended over catheter-
directed or systemic thrombolysis, or operative venous
thrombectomy. Patients with acute isolated distal DVT
of the leg and without severe symptoms or risk factors
for extension might not require initial anticoagulation,
but it is recommended that such patients be monitored
by serial imaging over a period of 2 weeks (7).
In patients with a high probability of acute DVTor PE,
immediate anticoagulation may be considered, even
pending the results of confirmatory diagnostic tests, but
the benefits should be weighed carefully against the risk
of bleeding in such situations (7). In contrast, patients
with a low probability of PE may have anticoagulation
withheld while awaiting test results, provided that results
are expected within 24 h. It is recommended that severe
or life-threatening PE that is associated with shock or
hypotension be treated with systemically administered
thrombolytic therapy (7). If necessary, pulmonary embo-
lectomy may be performed. Patients with nonsevere PE
may be treated with anticoagulants (7).
The ACCP also makes recommendations for those
cases in which treatment at home or early discharge can
be considered if the patient’s home circumstances are
adequate (Table 2). Adequate home circumstances are
defined as well-maintained living conditions, strong sup-
port from family or friends, phone access, and the ability
to quickly return to the hospital in case of deterioration.
Home treatment should be considered only if the patient
is feeling well enough and if the patient does not prefer
the security of treatment in the hospital over the conve-
nience and comfort of home (7). In patients who present
to the ED with acute DVT of the leg, the guidelinesTable 2. Circumstances Under Which Treatment at Home
or Early Discharge Can Be Considered (7)
Home circumstances
Well-maintained living conditions
Support from family and friends
Phone access
Able to quickly return to hospital if necessary
Other factors
Patient preference
Patient being well enough, for example, no severe leg
symptoms or comorbidityrecommend initial treatment at home over treatment in
the hospital (7). Moreover, in patients with low-risk PE,
the ACCP suggests early discharge over standard
discharge (e.g., after 5 days of treatment) (7).
Because acute PE is associated with a much higher
short-termmortality than acute DVT, the safety of treating
PE at home is less certain (7). Consequently, PE is treated
at home less frequently than DVT. Two studies have
confirmed that acute PE patients with a low risk of compli-
cations can be treated with LMWH as outpatients without
an increase in recurrent VTE, bleeding, or mortality (8,9).
Clinical trial data in patients with DVTor PE indicate that
a bridging strategy from a parenteral anticoagulant to
dabigatran or edoxaban, or a single-drug approach with
rivaroxaban or apixaban, are both viable treatment
alternatives (10–15). Unlike patients receiving VKAs,
who need to be monitored frequently after VKA
initiation until their INR is stabilized, the convenient
oral administration and fixed dosing regimen of selected
TSOACs offers the potential for early discharge and
increased patient satisfaction (5,16–18).
When considering type and duration of anticoagulation
therapy, the overall benefit–risk ratio should be consid-
ered. All anticoagulants are associated with an increased
risk of bleeding due to their mode of action. In general,
the risk of major bleeding is low with anticoagulants
approved for this indication. Factors that are indepen-
dently associated with an increased risk for major
bleeding include increasing age, co-medication use,
underlying conditions (such as hematological disease,
renal or hepatic disease, hypertension, and malignancy),
anemia, PE and recent bleeding, surgery, or trauma
(19–22). The Registro Informatizado de Pacientes con
Enfermedad TromboEmbo´lica (RIETE) registry also
validated a risk scoring system for major bleeding
during the first 3 months of anticoagulation therapy in
patients presenting with an acute VTE (Table 3) (21).
All of the above factors influence the decision on type,
dose, and duration of anticoagulation therapy.3 Months of Anticoagulant Treatment in Patients
with Acute Venous Thromboembolism (21)
Risk Factor Points
Recent major bleeding 2
Creatinine levels >1.2 mg/dL 1.5
Anemia 1.5
Age >75 years 1
Cancer at baseline 1
Pulmonary embolism diagnosis at baseline 1
Risk of major bleeding
High >4
Intermediate 1–4
Low 0
Table 4. Safety and Efficacy Outcomes of Phase III Trials with Target-specific Oral Anticoagulants for the Treatment of Acute
Venous Thromboembolism (10–15)
Treatment Arms
EINSTEIN DVT EINSTEIN PE RE-COVER
Rivaroxaban Enoxaparin/VKA Rivaroxaban Enoxaparin/VKA Heparin/Dabigatran Heparin/Warfarin
N (ITT) 1731 1718 2419 2413 1274 1265
N (safety) 1718 1711 2412 2405 1273 1266
Primary efficacy outcome†
n (%) 36 (2.1) 51 (3.0) 50 (2.1) 44 (1.8) 30 (2.4) 27 (2.1)
HR/RR (95% CI) HR 0.68 (0.44–1.04) HR 1.12 (0.75–1.68) HR 1.10 (0.65–1.84)
p-value <0.001 0.003 <0.001
Major bleeding‡
n (%) 14 (0.8) 20 (1.2) 26 (1.1) 52 (2.2) 20 (1.6) 24 (1.9)
HR/RR (95% CI) HR 0.65 (0.33–1.30) HR 0.49 (0.31–0.79) HR 0.82 (0.45–1.48)
p-value 0.21 0.003 NR
Major or nonmajor clinically relevant bleeding
n (%) 139 (8.1) 138 (8.1) 249 (10.3) 274 (11.4) 71 (5.6) 111 (8.8)
HR/RR (95% CI) HR 0.97 (0.76–1.22) HR 0.90 (0.76–1.07) HR 0.63 (0.47–0.84)
p-value 0.77 0.23 NR
CI = confidence interval; DVT = deep vein thrombosis; HR = hazard ratio; ITT = intention-to-treat; NR = not reported; PE = pulmonary
embolism; RR = relative risk; VKA = vitamin K antagonist; VTE = venous thromboembolism.
* Modified intention-to-treat and safety analysis.
† The primary efficacy outcome is defined as recurrent symptomatic VTE (composite of nonfatal or fatal DVT or PE) across studies.
‡ Major bleeding definitions are comparable across studies (clinically overt bleeding associated with a fall in the hemoglobin level of
$2 g/dL, or bleeding requiring transfusion of $2 units of blood or red cells, occurred in a critical site, or contributed to death).
§ p-value for superiority.
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Anticoagulants
The approvals of apixaban, dabigatran, edoxaban, and
rivaroxaban for the treatment of acute DVT or PE were
based on the results of randomized phase III clinical trials
(Table 4) (10–15).
Two separate randomized studies have been conducted
to evaluate rivaroxaban for the treatment of acute DVT
and PE. In the EINSTEIN studies, treatment duration
was 3, 6, or 12 months and patients received either rivar-
oxaban 15 mg twice daily for the first 3 weeks followed
by 20 mg once daily, or they received enoxaparin
1 mg/kg subcutaneously twice daily together with oral
VKA, followed by VKA alone once the INR was within
therapeutic range (2.0–3.0) (13,14). Because recurrent
events occur most likely immediately after presentation,
rapid and intensive treatment for the first 3 weeks in
patients with VTE is indicated as part of clot resolution,
and ensures that patients are adequately protected. In
a predefined safety analysis of the EINSTEIN PE
study, clot resolution within the first 21 days of
anticoagulation has been shown to be complete in
31–44% of patients, with a mean decrease in
pulmonary vascular obstruction of 62–71% (23). The
EINSTEIN DVT and EINSTEIN PE studies demon-
strated that rivaroxaban was noninferior to enoxaparin/
VKA for the prevention of recurrent VTE in patients
with acute DVT (2.1% vs. 3.0%, respectively;
p < 0.001) and in patients with PE with or without DVT(2.1% vs. 1.8%, respectively; p = 0.003). Rates of major
and nonmajor clinically relevant bleeding (defined as the
principal safety outcome) were similar in both treatment
arms (EINSTEIN DVT: 8.1% in both arms, p = 0.77;
EINSTEIN PE: 10.3% vs. 11.4%, respectively,
p = 0.23) (Table 4) (13,14). In EINSTEIN PE, the risk
of major bleeding was reduced by 51% with
rivaroxaban (1.1% vs. 2.2%, respectively; p = 0.003)
(Table 4). Importantly, in EINSTEIN PE, rivaroxaban
was associated with lower rates of intracranial hemor-
rhage (3 events [0.1%] vs. 13 events [0.5%]; fatal plus
nonfatal events, no p-value given) compared with enoxa-
parin/VKA. A pooled analysis of the EINSTEIN DVT
and EINSTEIN PE studies showed that there were signif-
icantly fewer first major bleeding events in the rivaroxa-
ban group compared with the enoxaparin/VKA group
(1.0% vs. 1.7%, respectively; p = 0.002). This difference
was primarily determined by reductions in the numbers of
intracranial (5 vs. 13, respectively), retroperitoneal (1 vs.
8, respectively), and gastrointestinal bleeding events
(including rectal and anal bleeding events: 15 vs. 26,
respectively). There were three fatal bleeding events in
the rivaroxaban group (<0.1%) and eight fatal bleeding
events in the enoxaparin/VKA group (0.2%) (24).
Based on the results of these studies, and outcomes
from a third study that evaluated extended treatment
with rivaroxaban (EINSTEIN EXT), rivaroxaban was
approved as a single-drug approach for the treatment of
DVT and PE and for the prevention of VTE recurrence
(13). Other TSOACs also have been evaluated for this
RE-COVER II AMPLIFY Hokusai-VTE*
Heparin/Dabigatran Heparin/Warfarin Apixaban Enoxaparin/Warfarin Heparin/Edoxaban Heparin/Warfarin
1279 1289 2691 2704 4118 4122
1279 1289 2676 2689 NR NR
30 (2.3) 28 (2.2) 59 (2.3) 71 (2.7) 130 (3.2) 146 (3.5)
HR 1.08 (0.64–1.80) RR 0.84 (0.60–1.18) HR 0.89 (0.70–1.13)
<0.001 <0.001 <0.001
15 (1.2) 22 (1.7) 15 (0.6) 49 (1.8) 56 (1.4) 66 (1.6)
HR 0.69 (0.36–1.32) RR 0.31 (0.17–0.55) HR 0.84 (0.59–1.21)
NR <0.001§ 0.35§
64 (5.0) 102 (7.9) 115 (4.3) 261 (9.7) 349 (8.5) 423 (10.3)
HR 0.62 (0.45–0.84) RR 0.44 (0.36–0.55) HR 0.81 (0.71–0.94)
NR <0.001 0.004§
Table 4. (Continued)
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patients with DVT or PE in the respective trials.
The AMPLIFY study compared apixaban (at a dose of
10 mg twice daily for 7 days, followed by 5 mg twice
daily) as a single-drug approach with enoxaparin/VKA
therapy for 6 months in patients with acute PE or DVT
(15). Apixaban was noninferior to enoxaparin/VKA for
the prevention of recurrent VTE and VTE-related death
(2.3% vs. 2.7%, respectively; p < 0.001) and was associ-
ated with significantly lower rates of major bleeding
events (0.6% vs. 1.8%, respectively; p < 0.001 for superi-
ority); which was defined as the principal safety outcome.
Apixaban was associated with lower rates of intracranial
hemorrhage (three events [0.1%] vs. six events [0.2%],
respectively) and gastrointestinal bleeding (seven events
[0.3%] vs. 18 events [0.7%], respectively). There was
one fatal bleeding event in the apixaban group and there
were two in the enoxaparin/VKA group. Rates of major
and nonmajor clinically relevant bleeding were signifi-
cantly lower in the apixaban group when compared to
the enoxaparin/VKA group (4.3% vs. 9.7%, respectively;
p < 0.001). Based on the results of this study, apixaban
was approved for the treatment of DVT and PE and for
the prevention of VTE recurrence.
Dabigatran was assessed in two phase III trials
for the treatment of acute VTE (RE-COVER and RE-
COVER II) (10,11). In both trials, the patients initially
received heparins (UFH or LMWH) for a median of
approximately 9 days, prior to treatment with dabigatran
at a dose of 150 mg twice daily or dose-adjusted warfarin(target INR 2.0–3.0) was initiated. Treatment duration in
both trials was 6 months. Dabigatran was shown to be non-
inferior to warfarin for the prevention of VTE recurrence
or VTE-related death (primary efficacy outcome) in both
phase III trials (RE-COVER: 2.4% vs. 2.1%, respectively,
hazard ratio [HR] 1.10, 95% confidence interval [CI]
0.65–1.84; RE-COVER II: 2.3% vs. 2.2%, respectively,
HR 1.08, 95% CI 0.64–1.80; p < 0.001) (Table 4). These
studies did not define a principal safety outcome, but the
rates of major bleeding events were similar in both treat-
ment arms (RE-COVER: 1.6% vs. 1.9%, respectively,
HR 0.82, 95% CI 0.45–1.48; RE-COVER II: 1.2% vs.
1.7%, HR 0.69, 95% CI 0.36–1.32) (Table 4) (10,11).
Rates of major and nonmajor clinically relevant bleeding
were significantly lower with dabigatran in both trials
(RE-COVER: 5.6% vs. 8.8%, respectively, HR 0.63,
95% CI 0.47–0.84; RE-COVER II: 5.0% vs. 7.9%, HR
0.62, 95% CI 0.45–0.84). The pooled analysis showed
that dabigatran had a trend to lower rates of intracranial
hemorrhage compared with warfarin (for the total on treat-
ment duration: two events [0.1%] vs. five events [0.2%]; no
p-value given). There was one fatal bleeding event in the
dabigatran group and two fatal bleeding events in the
warfarin group across both trials (10,11). Rates of death
and acute coronary syndrome were similar in both
treatment groups in RE-COVER and RE-COVER II
(11). Based on the results of these studies, dabigatran (after
5–10 days of parenteral therapy) was approved for the
treatment of VTE and for the prevention of VTE recur-
rence.
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study and compared the efficacy and safety of edoxaban
(at a dose of 60 mg once daily) with dose-adjusted
warfarin (target INR 2.0–3.0) for the treatment of acute
VTE after initial treatment with heparin for a median of
7 days in both study arms (12). Treatment duration was
3–12 months. Recurrence rates of VTE were similar in
the edoxaban and warfarin groups (3.2% vs. 3.5%,
respectively; p < 0.001 for noninferiority). Edoxaban
was associated with significantly lower rates of major
and nonmajor clinically relevant bleeding (defined
as the principal safety outcome) when compared with
warfarin (8.5% vs. 10.3%, respectively; p = 0.004 for
superiority). Rates of major bleeding events (1.4% vs.
1.6%; p = 0.35 for superiority) were similar in both treat-
ment groups, with lower rates of fatal bleeding events in
the edoxaban group (two events [<0.1%] vs. 10 events
[0.2%], respectively; no p-value given). Edoxaban was
also associated with lower rates of intracranial bleeding
(five events [0.1%] vs. 18 events [0.4%], respectively,
fatal plus nonfatal events; no p-value given).
What was the rationale for selecting either a single-
drug or a dual-drug approach for the respective phase
III clinical trials of these TSOACs? The main aim during
the initial phase of treatment for acute DVT or PE is the
prevention of thrombus extension and embolization and
thrombus regression, which can be achieved by intensive
anticoagulation. The two options explored in the previ-
ously described phase III trials are a higher daily dose
during the initial treatment phase (as in the case of apix-
aban and rivaroxaban) or conventional treatment with
injectable heparins (in the case of dabigatran andTable 5. Subgroup Analyses of the Acute Venous Thromboemboli
Treatment Arms
Recurrent VTE
Study Drug Comparator HR
Fragile patients*
EINSTEIN pooled, n/N (%) 21/791 (2.7) 30/782 (3.8) 0.68
Hokusai-VTE, n/N (%) 18/715 (2.5) 34/706 (4.8)
Elderly patients†
RE-COVER pooled, n/N (%) 3/253 (1.2) 5/276 (1.8)
Hokusai-VTE, n/N (%) 14/560 (2.5) 27/544 (5.0)
AMPLIFY, n/N (%) NR NR
Cancer patients with active cancer at baseline
EINSTEIN pooled, n/N (%) 16/316 (5.1) 20/281 (7.1) 0.69
RE-COVER pooled, n/N (%) 4/114 (3.5) 5/107 (4.7)
Hokusai-VTE, n/N (%) 4/109 (3.7) 7/99 (7.1)
Patients with prior VTE
EINSTEIN pooled, n/N (%) 11/791 (1.4) 25/819 (3.1) 0.45
RE-COVER pooled, n/N (%) 20/575 (3.5) 9/524 (1.7)
CI = confidence interval; CrCl = creatinine clearance; HR = hazard ratio
Data included only where available.
* EINSTEIN pooled defined fragile patients as those aged >75 years or c
VTE defined fragile patients as those aged $75 years, bodyweight #5
† Elderly patients were defined as being >75 years or $75 years of agedoxaban). In clinical practice, heparins are still routinely
used for the initial treatment of acute DVT or PE. Impor-
tantly, switching from heparins to any of the TSOACs is
straightforward, as noted by the European Heart Rhythm
Association guidelines (25).
Some patient subgroups have a high risk of bleeding in
addition to a high risk of VTE, and therefore pose specific
challenges. Data on the safety and efficacy of TSOACs
compared with standard of care in high-risk subgroups
are now available (Table 5) (11,12,15,26).
The results of phase III clinical trial data are encour-
aging, and it is likely that other TSOACs also will be
approved for the treatment of acute VTE. The character-
istics of TSOACs are expected to simplify VTE treatment
in patients presenting to the ED, including high-risk
patients.
Patients on Target-specific Oral Anticoagulants with
Bleeding Complications or Requiring Emergency
Surgery
The scope of this article does not allow a detailed discus-
sion of the management of diverse patient groups that
are taking TSOACs and who may present to the ED
with complications. However, certain aspects of the
practical management of TSOACs, such as the manage-
ment of bleeding complications, considerations ahead
of emergency invasive procedures or surgery, and–in
certain circumstances–the use of laboratory assays to
measure the coagulation status, are important when
patients on anticoagulants present to the ED, and are
highlighted below.sm Treatment Trials (11,12,15,26)
Major Bleeding
(95% CI) Study Drug Comparator HR (95% CI)
(0.39–1.18) 10/788 (1.3) 35/799 (4.5) 0.27 (0.13–0.54)
NR 79/715 (11.0) 97/706 (13.7) NR
NR NR NR NR
NR 70/560 (12.5) 82/544 (15.1) NR
NR 4/398 (1.0) 16/370 (4.3) NR
(0.36–1.33) 9/316 (2.8) 14/278 (5.0) 0.53 (0.23–1.23)
NR NR NR NR
NR 20/109 (18.3) 25/99 (25.3) NR
(0.22–0.91) 7/788 (0.9) 14/813 (1.7) 0.51 (0.21–1.27)
NR NR NR NR
; NR = not reported; VTE = venous thromboembolism.
alculated CrCl <50 mL/min or low bodyweight (#50 kg); Hokusai-
0 kg, or CrCl $30–#50 mL/min.
e.
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Strategies
Management of bleeding is a concern with any anti-
coagulant, but the real risk of bleeding depends on the
pharmacophysiological properties of the specific anti-
coagulant and patient-associated risk factors for bleeding.
Strategies encompass a range of approaches, including
cessation of therapy (because the half-life of many of
the TSOACs is relatively short), interruption or dose
adjustment of the anticoagulant, symptomatic interven-
tions, and occasionally, the use of reversal agents
(22,27). Currently, no clinically approved antidotes
exist for any of the TSOACs, but administration of
hemostatic procoagulant agents–prothrombin complex
concentrate (PCC), activated PCC, or recombinant
activated Factor VII–may be considered for life-
threatening bleeding events with apixaban, dabigatran,
and rivaroxaban; no such recommendations are made
for edoxaban (1–3,28). However, data on the
effectiveness of these agents in the clinical setting and
the subsequent risk of thromboembolism are very
limited to date. Nevertheless, reversal of rivaroxaban
anticoagulation has been demonstrated to occur within
30 min of PCC administration in healthy subjects,
suggesting potential utility in acute patient care (29,30).
Because plasma protein binding is low, dabigatran can
be dialyzed; however, clinical experience with this
approach is very limited (3,31). In contrast, apixaban,
edoxaban, and rivaroxaban are not dialyzable because
plasma protein binding is high.
Specific antidotes for Factor Xa inhibitors (PRT0
64445) and for dabigatran (humanized monoclonal
antibody fragment against dabigatran) are currently in
development and have shown promising results in initial
phase II studies and in animal model studies, respectively
(32–35).
In contrast to the TSOACs, the effect of VKAs can be
specifically reversed by the administration of vitamin K.
However, reversal with vitamin K is not immediate, and
this therapy alone is unlikely to be effective in life-
threatening emergency situations, even with intravenous
administration (5). Therefore, the ACCP guidelines
recommend the use of PCC in addition to vitamin K in
patients with VKA-associated major bleeding or those
requiring emergency anticoagulation reversal (36). With
this approach, correction of VKA-impaired hemostasis
can be achieved in under an hour (37).
Patients Who Need Emergency Surgery
In patients who are receiving TSOACs and require emer-
gency surgery, anticoagulation must be discontinued to
reduce the risk of bleeding, and the timing of the lastdose needs to be established. In these situations, the labo-
ratory assays can be used to measure the anticoagulant
activity or drug levels in plasma. If it is possible to delay
the emergency procedure, a delay of at least 24 h from
the last dose is recommended for rivaroxaban (i.e., when
rivaroxaban plasma concentration is at its lowest), and
a delay of 1–2 days after the last dose of dabigatran
(3–5 days for patients with creatinine clearance
<50 mL/min) or apixaban is recommended (1–3,28).
If surgery cannot be delayed, the increased risk of
bleeding must be weighed against the urgency of surgery.
After surgery, TSOACs can be restarted as soon as
adequate hemostasis has been established and provided
that the clinical situation allows the restart of therapy.
The time to onset of action with the TSOACs is relatively
short, and therefore, patients will be effectively anticoa-
gulated within a few hours after restarting therapy. If
the patient cannot receive oral medication, the adminis-
tration of a parenteral agent should be considered.
Laboratory Assays for Measuring Target-specific Oral
Anticoagulants
Routine coagulation monitoring is not necessary and not
recommended with any of the TSOACs. However, some
emergency situations (such as severe bleeding events,
bleeding at a critical site such as intraocular bleeding,
thromboembolic events, potential overdose, or need of
emergency surgery) may warrant measurement of coagu-
lation status. Importantly, any assessment of plasma
concentrations must be interpreted in relation to the
timing of the last drug administration and the patient’s
renal function.
INR monitoring tests were specifically developed
for VKAs and are not suitable for measuring TSOACs
(1–3,5,28). All TSOACs influence routine coagulation
tests (such as prothrombin time and activated partial
thromboplastin time), and therefore such tests are not
suitable for quantitative assessment of exposure
(Table 6) (1–4,38,39). Assays for the quantitative
measurement of Factor Xa inhibition (anti-Factor Xa
chromogenic assays) are commercially available, but
must be specifically ordered and may not be routinely
available (Table 6) (1). Dabigatran exposure can be deter-
mined by measurement of the ecarin clotting time, but
with the same assay caveats as for anti-Factor Xa chromo-
genic assays (Table 6) (40). Otherwise, the diluted
thrombin time or the activated partial thromboplastin
time may provide insight into the extent of dabigatran
exposure, but these results should be interpreted with
caution (3,40). The Hemoclot Thrombin Inhibitor kit
(Hyphen BioMed, Neuville-sur-Oise, France) is commer-
cially available and used with dabigatran calibrators and
controls (Table 6).
Table 6. Qualitative and Quantitative Laboratory Assays for Target-specific Oral Anticoagulants (1–4)
Coagulation Tests Dabigatran Apixaban Edoxaban Rivaroxaban
PT  Cannot be used
 Dabigatran prolongs PT, but
test has low sensitivity and
results vary between reagents
 Cannot be used
 Apixaban prolongs PT, but test
has low sensitivity and results
vary between reagents
 Edoxaban prolongs PT
 No known relation to bleeding
risk
 Rivaroxaban prolongs PT in a
linear and dose-dependent way
when using reagents sensitive
to rivaroxaban such as
Neoplastin Plus (Diagnostica
Stago, Asnie`res-sur-Seine,
France) or HemosIL
RecombiPlasTin 2G
(Instrumentation Laboratory,
Bedford, MA)
 Results vary according to the
thromboplastin reagent used
aPTT  Qualitative: >2  ULN at trough
drug concentration indicates
high bleeding risk
 The aPTT test has limited
sensitivity and is not suitable for
precise quantification of anti-
coagulant effect; high aPTT
values should be interpreted
with caution
 Cannot be used
 Apixaban prolongs aPTT, but
test has low sensitivity and
results vary between reagents
 Cannot be used
 Edoxaban prolongs aPTT
 No known relation to bleeding
risk
 Cannot be used
 The aPTT and HepTest are also
prolonged dose-dependently
but are not recommended for
assessing the anticoagulant
effect
dTT  Qualitative: >200 ng/mL or
>65 s at trough drug concen-
tration indicates high bleeding
risk
 Cannot be used  Cannot be used  Cannot be used
ECT  Qualitative:$3 ULN at trough
drug concentration indicates
high bleeding risk
 Cannot be used  Cannot be used  Cannot be used
Quantitative tests
(examples of
commercially
available tests)
Hemoclot thrombin inhibitor assay Rotachrom is an anti-Factor Xa
chromogenic assay* that is
recommended in the prescribing
information (2)
Currently no approved assays
available
Anti-Factor Xa chromogenic assays*,
such as Rotachrom, were shown
to accurately determine a wide
range of rivaroxaban
concentrations in plasma when
used with rivaroxaban calibrators
and controls (38,39)
aPTT = activated partial thromboplastin time; dTT = dilute thrombin time; ECT = ecarin clotting time; INR = international normalized ratio; PT = prothrombin time; ULN = upper limit of
normal.
* Anti-Factor Xa activity assays showed differences in their dynamic ranges (defined as 5% to 90% inhibition of baseline activity) when used to measure a specific TSOAC.
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Table 7. Summary of Drug–Drug Interactions with the Target-specific Oral Anticoagulants (1–4)
Name of Concomitant Drug Apixaban Rivaroxaban Dabigatran Etexilate Edoxaban
Strong inhibitors of both CYP3A4 and P-gp
Ketoconazole  In patients taking higher
doses than 2.5 mg b.i.d.:
reduce to half the dosewhen
used concomitantly
 Avoid concomitant use in
patients already taking
2.5 mg b.i.d. apixaban
 Avoid concomitant use  Consider reducing dose to
75 mg b.i.d. in patients with
moderate renal impairment
(CrCl 30–50 mL/min)
 Not recommended in patients
with severe renal impairment
Ritonavir  In patients taking higher
doses than 2.5 mg b.i.d.:
reduce to half the dosewhen
used concomitantly
 Avoid concomitant use in
patients already taking
2.5 mg b.i.d. apixaban
 Avoid concomitant use
Others  The reduced dose of
2.5 mg b.i.d. is also recom-
mended with other strong
dual inhibitors of CYP3A4
and P-gp, such as itracona-
zole and clarithromycin
 Avoid concomitant use
Strong inducers of both CYP3A4 and P-gp
Rifampin  Avoid concomitant use  Avoid concomitant use  Avoid concomitant use  Avoid concomitant use
Phenytoin, carbamazepine,
St. John’s wort
 Avoid concomitant use  Avoid concomitant use
NSAIDs/antiplatelet drugs
Chronic NSAIDs, for
example, diclofenac
 May increase risk of
bleeding
 May increase risk of bleeding  May increase risk of bleeding  May increase risk of bleeding
Acetylsalicylic acid  May increase risk of
bleeding
 May increase risk of bleeding  May increase risk of bleeding  May increase risk of bleeding
Clopidogrel  May increase risk of bleeding (41)  May increase risk of bleeding
b.i.d. = twice daily; CrCl = creatinine clearance; CYP3A4 = cytochrome P450 3A4; NSAID = nonsteroidal antiinflammatory drug; P-gp = P-glycoprotein.
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Anticoagulation in the Emergency Department 255Drug–Drug Interactions
Compared with VKAs, TSOACs have minimal drug–
drug interactions, but emergency physicians should be
aware of important pharmacokinetic effects resulting
from certain medications. Apixaban and rivaroxaban
are substrates for cytochrome P450 (CYP) 3A4 and
also for the cell efflux transporter P-glycoprotein (P-gp)
(1,28). Therefore, specific recommendations are in
place for the co-administration of rivaroxaban or apixa-
ban with strong inhibitors of both CYP3A4 and P-gp,
such as azole-antimycotics or HIV protease inhibitors
(Table 7), because co-administration with these agents
may increase plasma concentrations of apixaban and
rivaroxaban and the risk of bleeding. In addition, rivarox-
aban and apixaban should be used with caution in patients
receiving strong inducers of both CYP3A4 and P-gp.
Dabigatran uptake is dependent on P-gp transporters
and therefore, concomitant medication with any P-gp
inhibitor or inducer properties may require dose adjust-
ments or should be avoided altogether (Table 7)
(1–4,28,41). Moreover, medicinal products that affect
hemostasis, such as nonsteroidal antiinflammatory
drugs, acetylsalicylic acid, and platelet aggregation
inhibitors, typically increase the risk of bleeding, and
therefore should be used with caution when co-
administered with any of the three agents. An in-depth
discussion of drug–drug interactions of TSOACs has
recently been published (42).
CONCLUSION
Emergency physicians are responsible for the initial diag-
nosis and management of patients who present with acute
DVT or PE. The U.S. Food and Drug Administration and
the European Medicines Agency approval of rivaroxaban
and, more recently, of apixaban, dabigatran, and edoxa-
ban, for the treatment of acute DVT or PE marks a
substantial change in the currently accepted treatment
options for the management of acute VTE. Physicians
now have the option to prescribe apixaban and rivaroxa-
ban as single-drug approaches, and dabigatran and edox-
aban as dual-drug approaches for the treatment of acute
DVT or PE. Moreover, with approvals of these TSOACs
for various thromboembolic disorders, the number of
patients presenting to the ED who will be taking these
anticoagulants is likely to increase. It is essential,
therefore, that emergency physicians are familiar with
practical issues relating to the management of patients
taking these drugs, and can respond accordingly.
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1. Why is this topic important?
New approvals and increasing prescriptions of target-
specific oral anticoagulants (TSOACs), formerly termed
‘‘novel oral anticoagulants’’ (NOACs; e.g., apixaban, da-
bigatran, and rivaroxaban), for the management of several
thromboembolic disorders warrant an evaluation of the
impact of these agents in the emergency department
(ED) setting.
2. What does this review attempt to show?
The objectives of this article are to discuss the potential
impact of the use of TSOACs in the ED for the treatment
of acute thromboembolic disorders and to discuss strate-
gies for the management of patients on TSOACs who pre-
sent to the ED with complications.
3. What are the key findings?
TSOACs provide alternative options to traditional ther-
apy for the treatment of acute venous thromboembolism
(VTE) with the potential benefit of simplified patient
management. Moreover, key practical management stra-
tegies for patients on anticoagulants presenting to the
ED are similar among different TSOACs.
4. How is patient care impacted?
The characteristics of TSOACs should simplify the
management of VTE treatment in patients presenting to
the ED, including high-risk patients such as fragile or
elderly patients, patients with cancer, and patients with
prior VTE. Emergency physicians will be able to provide
patients with the best possible care by being familiar with
the appropriate use of TSOACs and practical issues
relating to the management of patients taking these drugs.
